Noriaki Matsumoto

Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)

Hiroyuki Abé, Shinichi Kikuchi, Kazuhide Hayakawa et al. · ACS Medicinal Chemistry Letters · 2011 · 185 citations · Full text

Chemoprevention Strategy, Selective Mek Inhibitor, New Generation +22

Aβ(25–35)-Induced Memory Impairment, Axonal Atrophy, and Synaptic Loss are Ameliorated by M1, A Metabolite of Protopanaxadiol-Type Saponins

Chihiro Tohda, Noriaki Matsumoto, Kun Zou et al. · Neuropsychopharmacology · 2003 · 139 citations · Full text

Protopanaxadiol-type Saponins, Synaptic Plasticity, Neurodegenerative Diseases +15

Direct, practical, and powerful crossed aldol additions between ketones and ketones or aldehydes utilizing environmentally benign TiCl4–Bu3N reagent

Yoo Tanabe, Noriaki Matsumoto, Takahiro Higashi et al. · Tetrahedron · 2002 · 74 citations

Engineering, Benign Ticl4–bu3n Reagent, Organic Chemistry +5

Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation

Yuji Kishimoto, Y. Yamamoto, Tomoki� Ito et al. · Bone Marrow Transplantation · 1997 · 66 citations

Transplant Rejection, Autoimmune Disease, Medicine +11

Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome

Noriaki Matsumoto, Noriko Yoneda‐Kato, Tomoko Iguchi et al. · Leukemia · 2000 · 53 citations

Hematological Malignancy, Mlf1 Expression Correlates, Medicine +9